ID   DRD4_HUMAN              Reviewed;         419 AA.
AC   P21917; B0M0J7; Q7Z7Q5; Q8NGM5;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   10-APR-2019, sequence version 3.
DT   07-APR-2021, entry version 197.
DE   RecName: Full=D(4) dopamine receptor;
DE   AltName: Full=D(2C) dopamine receptor;
DE   AltName: Full=Dopamine D4 receptor;
GN   Name=DRD4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE D4.7), POLYMORPHISM, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=1319557; DOI=10.1038/358149a0;
RA   van Tol H.H., Wu C.M., Guan H.C., Ohara K., Bunzow J.R., Civelli O.,
RA   Kennedy J., Seeman P., Niznik H.B., Jovanovic V.;
RT   "Multiple dopamine D4 receptor variants in the human population.";
RL   Nature 358:149-152(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE D4.2), FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Brain;
RX   PubMed=1840645; DOI=10.1038/350610a0;
RA   van Tol H.H.M., Bunzow J.R., Guan H.-C., Sunahara R.K., Seeman P.,
RA   Niznik H.B., Civelli O.;
RT   "Cloning of the gene for a human dopamine D4 receptor with high affinity
RT   for the antipsychotic clozapine.";
RL   Nature 350:610-614(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE D.4.4).
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE D.4.4).
RC   TISSUE=Brain;
RA   Kaighin V.A., Martin A.L., Aronstam R.S.;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE D4.4).
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE D.4.4).
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   POLYMORPHISM.
RX   PubMed=8353495; DOI=10.1093/hmg/2.6.767;
RA   Lichter J.B., Barr C.L., Kennedy J.L., Van Tol H.H., Kidd K.K., Livak K.J.;
RT   "A hypervariable segment in the human dopamine receptor D4 (DRD4) gene.";
RL   Hum. Mol. Genet. 2:767-773(1993).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=7512953;
RA   Chio C.L., Drong R.F., Riley D.T., Gill G.S., Slightom J.L., Huff R.M.;
RT   "D4 dopamine receptor-mediated signaling events determined in transfected
RT   Chinese hamster ovary cells.";
RL   J. Biol. Chem. 269:11813-11819(1994).
RN   [9]
RP   POLYMORPHISM, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=8078498;
RA   Asghari V., Schoots O., van Kats S., Ohara K., Jovanovic V., Guan H.-C.,
RA   Bunzow J.R., Petronis A., Van Tol H.H.M.;
RT   "Dopamine D4 receptor repeat: analysis of different native and mutant forms
RT   of the human and rat genes.";
RL   Mol. Pharmacol. 46:364-373(1994).
RN   [10]
RP   TISSUE SPECIFICITY.
RX   PubMed=7769992; DOI=10.1016/0169-328x(94)00245-a;
RA   Matsumoto M., Hidaka K., Tada S., Tasaki Y., Yamaguchi T.;
RT   "Full-length cDNA cloning and distribution of human dopamine D4 receptor.";
RL   Brain Res. Mol. Brain Res. 29:157-162(1995).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=7643093; DOI=10.1046/j.1471-4159.1995.65031157.x;
RA   Asghari V., Sanyal S., Buchwaldt S., Paterson A., Jovanovic V.,
RA   Van Tol H.H.;
RT   "Modulation of intracellular cyclic AMP levels by different human dopamine
RT   D4 receptor variants.";
RL   J. Neurochem. 65:1157-1165(1995).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=9003072; DOI=10.1046/j.1471-4159.1997.68020804.x;
RA   Lanau F., Zenner M.T., Civelli O., Hartman D.S.;
RT   "Epinephrine and norepinephrine act as potent agonists at the recombinant
RT   human dopamine D4 receptor.";
RL   J. Neurochem. 68:804-812(1997).
RN   [13]
RP   INTERACTION WITH GPRASP1.
RX   PubMed=12142540; DOI=10.1126/science.1073308;
RA   Whistler J.L., Enquist J., Marley A., Fong J., Gladher F., Tsuruda P.,
RA   Murray S.R., Von Zastrow M.;
RT   "Modulation of postendocytic sorting of G protein-coupled receptors.";
RL   Science 297:615-620(2002).
RN   [14]
RP   FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND POLYMORPHISM.
RX   PubMed=16423344; DOI=10.1016/j.ejphar.2005.11.063;
RA   Czermak C., Lehofer M., Liebmann P.M., Traynor J.;
RT   "[35S]GTPgammaS binding at the human dopamine D4 receptor variants hD4.2,
RT   hD4.4 and hD4.7 following stimulation by dopamine, epinephrine and
RT   norepinephrine.";
RL   Eur. J. Pharmacol. 531:20-24(2006).
RN   [15]
RP   UBIQUITINATION, AND INTERACTION WITH KLHL12.
RX   PubMed=18303015; DOI=10.1074/jbc.m708473200;
RA   Rondou P., Haegeman G., Vanhoenacker P., Van Craenenbroeck K.;
RT   "BTB Protein KLHL12 targets the dopamine D4 receptor for ubiquitination by
RT   a Cul3-based E3 ligase.";
RL   J. Biol. Chem. 283:11083-11096(2008).
RN   [16]
RP   POSSIBLE INTERACTION WITH ADORA2A.
RX   PubMed=20836733; DOI=10.3109/10799893.2010.513842;
RA   Woods A.S.;
RT   "The dopamine D(4) receptor, the ultimate disordered protein.";
RL   J. Recept. Signal Transduct. 30:331-336(2010).
RN   [17]
RP   UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=20100572; DOI=10.1016/j.cellsig.2010.01.014;
RA   Rondou P., Skieterska K., Packeu A., Lintermans B., Vanhoenacker P.,
RA   Vauquelin G., Haegeman G., Van Craenenbroeck K.;
RT   "KLHL12-mediated ubiquitination of the dopamine D4 receptor does not target
RT   the receptor for degradation.";
RL   Cell. Signal. 22:900-913(2010).
RN   [18]
RP   HOMOOLIGOMERIZATION, AND INTERACTION WITH DRD2.
RX   PubMed=21184734; DOI=10.1016/j.bbrc.2010.12.083;
RA   Borroto-Escuela D.O., Van Craenenbroeck K., Romero-Fernandez W.,
RA   Guidolin D., Woods A.S., Rivera A., Haegeman G., Agnati L.F.,
RA   Tarakanov A.O., Fuxe K.;
RT   "Dopamine D2 and D4 receptor heteromerization and its allosteric receptor-
RT   receptor interactions.";
RL   Biochem. Biophys. Res. Commun. 404:928-934(2011).
RN   [19]
RP   PALMITOYLATION AT CYS-419, MUTAGENESIS OF CYS-418 AND CYS-419, SUBCELLULAR
RP   LOCATION, AND FUNCTION.
RX   PubMed=27659709; DOI=10.1016/j.bbrc.2016.09.094;
RA   Zhang X., Kim K.M.;
RT   "Palmitoylation of the carboxyl-terminal tail of dopamine D4 receptor is
RT   required for surface expression, endocytosis, and signaling.";
RL   Biochem. Biophys. Res. Commun. 479:398-403(2016).
RN   [20]
RP   3D-STRUCTURE MODELING.
RX   PubMed=1358063; DOI=10.1042/bj2870277;
RA   Livingstone C.D., Strange P.G., Naylor L.H.;
RT   "Molecular modelling of D2-like dopamine receptors.";
RL   Biochem. J. 287:277-282(1992).
RN   [21] {ECO:0007744|PDB:5WIU, ECO:0007744|PDB:5WIV}
RP   X-RAY CRYSTALLOGRAPHY (1.96 ANGSTROMS) OF 1-228 AND 335-419 IN COMPLEX WITH
RP   NEMONAPRIDE, FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, TOPOLOGY,
RP   DISULFIDE BONDS, AND MUTAGENESIS OF VAL-382.
RX   PubMed=29051383; DOI=10.1126/science.aan5468;
RA   Wang S., Wacker D., Levit A., Che T., Betz R.M., McCorvy J.D.,
RA   Venkatakrishnan A.J., Huang X.P., Dror R.O., Shoichet B.K., Roth B.L.;
RT   "D4 dopamine receptor high-resolution structures enable the discovery of
RT   selective agonists.";
RL   Science 358:381-386(2017).
RN   [22]
RP   VARIANT GLY-194.
RX   PubMed=7726213; DOI=10.1002/ajmg.1320540419;
RA   Seeman P., Ulpian C., Chouinard G., van Tol H.H.M., Dwosh H.,
RA   Lieberman J.A., Siminovitch K., Liu I.S.C., Waye J., Voruganti P.,
RA   Hudson C., Serjeant G.R., Masibay A.S., Seeman M.V.;
RT   "Dopamine D4 receptor variant, D4-glycine-194, in Africans, but not in
RT   Caucasians: no association with schizophrenia.";
RL   Am. J. Med. Genet. 54:384-390(1994).
CC   -!- FUNCTION: Dopamine receptor responsible for neuronal signaling in the
CC       mesolimbic system of the brain, an area of the brain that regulates
CC       emotion and complex behavior. Activated by dopamine, but also by
CC       epinephrine and norepinephrine, and by numerous synthetic agonists and
CC       drugs (PubMed:9003072, PubMed:16423344, PubMed:27659709,
CC       PubMed:29051383). Agonist binding triggers signaling via G proteins
CC       that inhibit adenylyl cyclase (PubMed:7512953, PubMed:7643093,
CC       PubMed:16423344, PubMed:27659709, PubMed:29051383). Modulates the
CC       circadian rhythm of contrast sensitivity by regulating the rhythmic
CC       expression of NPAS2 in the retinal ganglion cells (By similarity).
CC       {ECO:0000250|UniProtKB:P51436, ECO:0000269|PubMed:16423344,
CC       ECO:0000269|PubMed:1840645, ECO:0000269|PubMed:27659709,
CC       ECO:0000269|PubMed:29051383, ECO:0000269|PubMed:7512953,
CC       ECO:0000269|PubMed:7643093, ECO:0000269|PubMed:8078498,
CC       ECO:0000269|PubMed:9003072}.
CC   -!- ACTIVITY REGULATION: Signaling in response to agonists such as
CC       dopamine, epinephrine and norepinephrine is modulated by Na(+); lower
CC       Na(+) levels result in higher receptor activity (in vitro).
CC       {ECO:0000269|PubMed:16423344, ECO:0000269|PubMed:29051383}.
CC   -!- SUBUNIT: Forms homo- and heterooligomers with DRD2. D4.7 allele
CC       exhibits higher affinity for homodimers compared to DRD2 heterodimers,
CC       while alleles D42. and 4.4 have similar affinities for both. The
CC       interaction with DRD2 may modulate agonist-induced downstream signaling
CC       (PubMed:21184734). Interacts with CLIC6 (By similarity). Interacts with
CC       GPRASP1 (PubMed:12142540). May interact with ADORA2A (PubMed:20836733).
CC       Interacts with KLHL12 (PubMed:18303015). {ECO:0000250|UniProtKB:P30729,
CC       ECO:0000269|PubMed:12142540, ECO:0000269|PubMed:18303015,
CC       ECO:0000269|PubMed:21184734}.
CC   -!- INTERACTION:
CC       P21917; P05067: APP; NbExp=6; IntAct=EBI-8592297, EBI-77613;
CC       P21917; P21917: DRD4; NbExp=5; IntAct=EBI-8592297, EBI-8592297;
CC       P21917; P17677: GAP43; NbExp=3; IntAct=EBI-8592297, EBI-1267511;
CC       P21917; P50579: METAP2; NbExp=3; IntAct=EBI-8592297, EBI-2214155;
CC       P21917; Q96P71-2: NECAB3; NbExp=3; IntAct=EBI-8592297, EBI-15098952;
CC       P21917; P61764: STXBP1; NbExp=3; IntAct=EBI-8592297, EBI-960169;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1319557,
CC       ECO:0000269|PubMed:16423344, ECO:0000269|PubMed:1840645,
CC       ECO:0000269|PubMed:20100572, ECO:0000269|PubMed:27659709,
CC       ECO:0000269|PubMed:29051383, ECO:0000269|PubMed:7512953,
CC       ECO:0000269|PubMed:7643093, ECO:0000269|PubMed:8078498,
CC       ECO:0000269|PubMed:9003072}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:20100572, ECO:0000269|PubMed:29051383}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in retina. Detected at much lower
CC       levels in brain, in amygdala, thalamus, hypothalamus, cerebellum and
CC       pituitary. {ECO:0000269|PubMed:7769992}.
CC   -!- PTM: Polyubiquitinated by the BCR(KLHL12) E3 ubiquitin ligase complex:
CC       polyubiquitination does not lead to degradation of DRD4 protein.
CC       {ECO:0000269|PubMed:18303015, ECO:0000269|PubMed:20100572}.
CC   -!- PTM: Palmitoylated. Palmitoylation of the C-terminal Cys is important
CC       for normal expression at the cell membrane.
CC       {ECO:0000269|PubMed:27659709}.
CC   -!- POLYMORPHISM: The number of repeats of 16 amino acids in the third
CC       cytoplasmic loop is highly polymorphic and varies among different
CC       alleles. Alleles corresponding in size to a 2 (D4.2), 3 (D4.3), 4
CC       (D4.4), 5 (D4.5), 6 (D4.6), 7 (D4.7) and 9 (D4.9) repeats have been
CC       described. The sequence shown is that of allele D4.4. The polymorphic
CC       repeat sequence has little influence on DRD4-binding profiles and might
CC       not be essential for G protein interaction.
CC       {ECO:0000269|PubMed:1319557, ECO:0000269|PubMed:16423344,
CC       ECO:0000269|PubMed:8078498, ECO:0000269|PubMed:8353495}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL58637.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L12398; AAB59386.1; -; mRNA.
DR   EMBL; L12397; AAL58637.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AB065765; BAC05985.1; -; Genomic_DNA.
DR   EMBL; EU432112; ABY87911.1; -; mRNA.
DR   EMBL; AP006284; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471158; EAX02369.1; -; Genomic_DNA.
DR   CCDS; CCDS7710.1; -.
DR   PIR; S15079; DYHUD4.
DR   PIR; S24195; S24195.
DR   RefSeq; NP_000788.2; NM_000797.3.
DR   PDB; 5WIU; X-ray; 1.96 A; A=1-228, A=335-419.
DR   PDB; 5WIV; X-ray; 2.14 A; A=1-228, A=335-419.
DR   PDBsum; 5WIU; -.
DR   PDBsum; 5WIV; -.
DR   SMR; P21917; -.
DR   BioGRID; 108149; 14.
DR   CORUM; P21917; -.
DR   DIP; DIP-59865N; -.
DR   IntAct; P21917; 8.
DR   MINT; P21917; -.
DR   BindingDB; P21917; -.
DR   ChEMBL; CHEMBL219; -.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00490; Buspirone.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB11275; Epicriptine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB04908; Flibanserin.
DR   DrugBank; DB04946; Iloperidone.
DR   DrugBank; DB01235; Levodopa.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB12061; Pardoprunox.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB08922; Perospirone.
DR   DrugBank; DB09286; Pipamperone.
DR   DrugBank; DB00413; Pramipexole.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00409; Remoxipride.
DR   DrugBank; DB00268; Ropinirole.
DR   DrugBank; DB05271; Rotigotine.
DR   DrugBank; DB06477; Sumanirole.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P21917; -.
DR   GuidetoPHARMACOLOGY; 217; -.
DR   GlyGen; P21917; 1 site.
DR   iPTMnet; P21917; -.
DR   PhosphoSitePlus; P21917; -.
DR   BioMuta; DRD4; -.
DR   DMDM; 1345939; -.
DR   MassIVE; P21917; -.
DR   PeptideAtlas; P21917; -.
DR   PRIDE; P21917; -.
DR   ProteomicsDB; 53940; -.
DR   Antibodypedia; 22579; 453 antibodies.
DR   DNASU; 1815; -.
DR   Ensembl; ENST00000176183; ENSP00000176183; ENSG00000069696.
DR   Ensembl; ENST00000611962; ENSP00000478431; ENSG00000276825.
DR   GeneID; 1815; -.
DR   KEGG; hsa:1815; -.
DR   UCSC; uc001lqp.3; human.
DR   CTD; 1815; -.
DR   DisGeNET; 1815; -.
DR   GeneCards; DRD4; -.
DR   HGNC; HGNC:3025; DRD4.
DR   HPA; ENSG00000069696; Tissue enriched (retina).
DR   MalaCards; DRD4; -.
DR   MIM; 126452; gene.
DR   neXtProt; NX_P21917; -.
DR   OpenTargets; ENSG00000069696; -.
DR   PharmGKB; PA27480; -.
DR   VEuPathDB; HostDB:ENSG00000069696.6; -.
DR   GeneTree; ENSGT00940000160974; -.
DR   HOGENOM; CLU_009579_11_1_1; -.
DR   InParanoid; P21917; -.
DR   OMA; VVHITQA; -.
DR   OrthoDB; 1215361at2759; -.
DR   PhylomeDB; P21917; -.
DR   TreeFam; TF334382; -.
DR   PathwayCommons; P21917; -.
DR   Reactome; R-HSA-390651; Dopamine receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P21917; -.
DR   BioGRID-ORCS; 1815; 3 hits in 980 CRISPR screens.
DR   ChiTaRS; DRD4; human.
DR   GeneWiki; Dopamine_receptor_D4; -.
DR   GenomeRNAi; 1815; -.
DR   Pharos; P21917; Tchem.
DR   PRO; PR:P21917; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P21917; protein.
DR   Bgee; ENSG00000069696; Expressed in muscle tissue and 106 other tissues.
DR   Genevisible; P21917; HS.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:SYSCILIA_CCNET.
DR   GO; GO:0098794; C:postsynapse; IEA:GOC.
DR   GO; GO:0035240; F:dopamine binding; IDA:UniProtKB.
DR   GO; GO:0004952; F:dopamine neurotransmitter receptor activity; IDA:BHF-UCL.
DR   GO; GO:0001591; F:dopamine neurotransmitter receptor activity, coupled via Gi/Go; IDA:UniProtKB.
DR   GO; GO:0051379; F:epinephrine binding; IDA:UniProtKB.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0051380; F:norepinephrine binding; IDA:UniProtKB.
DR   GO; GO:0015459; F:potassium channel regulator activity; NAS:BHF-UCL.
DR   GO; GO:0017124; F:SH3 domain binding; IDA:BHF-UCL.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:BHF-UCL.
DR   GO; GO:0007195; P:adenylate cyclase-inhibiting dopamine receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008344; P:adult locomotory behavior; ISS:BHF-UCL.
DR   GO; GO:0050482; P:arachidonic acid secretion; IDA:BHF-UCL.
DR   GO; GO:0001662; P:behavioral fear response; NAS:BHF-UCL.
DR   GO; GO:0048148; P:behavioral response to cocaine; ISS:BHF-UCL.
DR   GO; GO:0048149; P:behavioral response to ethanol; TAS:BHF-UCL.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IC:BHF-UCL.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0042417; P:dopamine metabolic process; IC:BHF-UCL.
DR   GO; GO:0007212; P:dopamine receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042596; P:fear response; ISS:BHF-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0060080; P:inhibitory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:0050709; P:negative regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:1901386; P:negative regulation of voltage-gated calcium channel activity; IDA:BHF-UCL.
DR   GO; GO:0051586; P:positive regulation of dopamine uptake involved in synaptic transmission; IC:BHF-UCL.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IDA:BHF-UCL.
DR   GO; GO:0032417; P:positive regulation of sodium:proton antiporter activity; IDA:BHF-UCL.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0042053; P:regulation of dopamine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0099149; P:regulation of postsynaptic neurotransmitter receptor internalization; IEA:Ensembl.
DR   GO; GO:0001975; P:response to amphetamine; ISS:BHF-UCL.
DR   GO; GO:0034776; P:response to histamine; IDA:BHF-UCL.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0035176; P:social behavior; NAS:BHF-UCL.
DR   InterPro; IPR002185; Dopamine_D4_rcpt.
DR   InterPro; IPR000929; Dopamine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24248:SF143; PTHR24248:SF143; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00569; DOPAMINED4R.
DR   PRINTS; PR00242; DOPAMINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Biological rhythms; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Metal-binding; Palmitate; Receptor; Reference proteome; Repeat; Sodium;
KW   Transducer; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN           1..419
FT                   /note="D(4) dopamine receptor"
FT                   /id="PRO_0000069401"
FT   TOPO_DOM        1..29
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        30..50
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        51..71
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        72..92
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        93..110
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        111..131
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        132..152
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        153..173
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        174..192
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        193..213
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        214..346
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        347..367
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        368..382
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        383..403
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        404..419
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   REPEAT          249..264
FT                   /note="1; approximate"
FT   REPEAT          265..280
FT                   /note="2"
FT   REPEAT          281..296
FT                   /note="3"
FT   REPEAT          297..312
FT                   /note="4; approximate"
FT   REGION          249..312
FT                   /note="4 X 16 AA approximate tandem repeats of [PA]-A-P-G-
FT                   L-P-[PQR]-[DG]-P-C-G-P-D-C-A-P"
FT   METAL           80
FT                   /note="Sodium"
FT                   /evidence="ECO:0000305|PubMed:29051383"
FT   METAL           122
FT                   /note="Sodium"
FT                   /evidence="ECO:0000305|PubMed:29051383"
FT   BINDING         115
FT                   /note="Agonist"
FT                   /evidence="ECO:0000305|PubMed:29051383"
FT   LIPID           419
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:27659709"
FT   CARBOHYD        3
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        108..185
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:29051383, ECO:0007744|PDB:5WIU,
FT                   ECO:0007744|PDB:5WIV"
FT   DISULFID        372..375
FT                   /evidence="ECO:0000269|PubMed:29051383,
FT                   ECO:0007744|PDB:5WIU, ECO:0007744|PDB:5WIV"
FT   VARIANT         194
FT                   /note="V -> G (in dbSNP:rs1800443)"
FT                   /evidence="ECO:0000269|PubMed:7726213"
FT                   /id="VAR_003464"
FT   VARIANT         265..296
FT                   /note="Missing (in allele D4.2)"
FT                   /evidence="ECO:0000269|PubMed:1840645"
FT                   /id="VAR_003465"
FT   VARIANT         284
FT                   /note="S -> GLPPDPCGPDCAPPAPGLPQDPCGPDCAPPAPGLPRGPCGPDCAPPA
FT                   PG (in allele D4.7)"
FT                   /evidence="ECO:0000269|PubMed:1319557"
FT                   /id="VAR_081438"
FT   MUTAGEN         382
FT                   /note="V->Y: Increased basal level of G protein-mediated
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   MUTAGEN         418
FT                   /note="C->G: No effect on palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:27659709"
FT   MUTAGEN         419
FT                   /note="C->G: Loss of palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:27659709"
FT   CONFLICT        237
FT                   /note="R -> F (in Ref. 2; BAC05985)"
FT                   /evidence="ECO:0000305"
FT   HELIX           35..61
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           63..65
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           68..86
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           88..96
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   TURN            97..99
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           105..138
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   STRAND          144..147
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           151..171
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           190..200
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   TURN            201..203
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           204..220
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           340..344
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           347..371
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           379..403
FT                   /evidence="ECO:0007744|PDB:5WIU"
FT   HELIX           405..412
FT                   /evidence="ECO:0007744|PDB:5WIU"
SQ   SEQUENCE   419 AA;  43901 MW;  34CBE8320302008E CRC64;
     MGNRSTADAD GLLAGRGPAA GASAGASAGL AGQGAAALVG GVLLIGAVLA GNSLVCVSVA
     TERALQTPTN SFIVSLAAAD LLLALLVLPL FVYSEVQGGA WLLSPRLCDA LMAMDVMLCT
     ASIFNLCAIS VDRFVAVAVP LRYNRQGGSR RQLLLIGATW LLSAAVAAPV LCGLNDVRGR
     DPAVCRLEDR DYVVYSSVCS FFLPCPLMLL LYWATFRGLQ RWEVARRAKL HGRAPRRPSG
     PGPPSPTPPA PRLPQDPCGP DCAPPAPGLP RGPCGPDCAP AAPSLPQDPC GPDCAPPAPG
     LPPDPCGSNC APPDAVRAAA LPPQTPPQTR RRRRAKITGR ERKAMRVLPV VVGAFLLCWT
     PFFVVHITQA LCPACSVPPR LVSAVTWLGY VNSALNPVIY TVFNAEFRNV FRKALRACC
//
